Mitochondria in the striatum of subjects with schizophrenia

World Journal of Biological Psychiatry

Volumn 12, Issue 1, 2011, Pages 48-56

  Somerville, Shahza M ^a,b   Conley, Robert R ^b,d   Roberts, Rosalinda C ^b,c  

^a UNIVERSITY OF MARYLAND BALTIMORE COUNTY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d Lilly Technology Center   (United States)

Author keywords

antipsychotics; Caudate nucleus; neuropathology; schizophrenia; ultrastructure

Indexed keywords

CHLORPROMAZINE; FLUPHENAZINE; HALOPERIDOL; LOXAPINE; OLANZAPINE; PERPHENAZINE; RISPERIDONE;

ADULT; ARTICLE; CADAVER; CAUDATE NUCLEUS; CELL DENSITY; CELL ULTRASTRUCTURE; CONTROLLED STUDY; CORPUS STRIATUM; DENDRITE; FEMALE; HUMAN; HUMAN TISSUE; MALE; MITOCHONDRION; PUTAMEN; SCHIZOPHRENIA; SYNAPSE;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; CAUDATE NUCLEUS; CORPUS STRIATUM; FEMALE; HUMANS; MALE; MICROSCOPY, ELECTRON; MIDDLE AGED; MITOCHONDRIA; PUTAMEN; SCHIZOPHRENIA;

EID: 79551590226     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622975.2010.505662     Document Type: Article

References (73)

1. Alexander GE, DeLong MR, Strick PL. 1986. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Ann Rev Neurosci 9:357-381.
2. Alexander GE, Crutcher MD, DeLong MR. 1990. Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, ' prefrontal ' and ' limbic ' functions. Prog Brain Res 85: 119-146.
3. American Psychiatric Association. 1994. Diagnostic and statistical manual of mental disorders. Washington, DC: American Psychiatric Press.
4. Andersson C, Hamer RM, Lawler CP, Mailman RB, Lieberman JA. 2002. Striatal volume changes in the rat following long-term administration of typical and atypical antipsychotic drugs. Neu-ropsychopharmacology 27(2):143-51.
5. Ben-Shachar D. 2002. Mitochondrial dysfunction in schizophrenia: a possible linkage to dopamine. J Neurochem 83(6): 1241-1251.
6. Ben-Shachar D, Karry R. 2008. Neuroanatomical pattern of mitochondrial complex I pathology varies between schizophrenia, bipolar disorder and major depression. PLoS One 3(11):3676-3688.
7. Ben-Shachar D, Laifenfeld D. 2004. Mitochondria, synaptic plasticity, and schizophrenia. International Review of Neurobiology. New York: Academic Press. p. 273-296.
8. Ben-Shachar D, Zuk R, Gazawi H, Reshef A, Sheinkman A, Klein E. 1999. Increased mitochondrial complex I activity in platelets of schizophrenic patients. Int J Neuropsychopharmacol 4: 245-253.
9. Ben-Shachar D, Bonne O, Chisin R, Klein E, Lester H, Aharon-Peretz J, et al. 2007. Cerebral glucose utilization and platelet mitochondrial complex I activity in schizophrenia: A FDG-PET study. Prog Neuropsychopharmacol Biol Psychiatr 4:807-813.
10. Bokura H, Robinson RG. 1997. Long-term cognitive impairment associated with caudate stroke. Stroke 28(5):970-975.
11. Buchsbaum MS, Haier RJ, Potkin SG, Nuechterlein K, Bracha HS, Katz M, et al. 1992a. Frontostriatal disorder of cerebral metabolism in never-medicated schizophrenics. Arch Gen Psychiatr 49:935-942.
12. Buchsbaum MS, Potkin SG, Siegel BV Jr, Lohr J, Katz M, Gottschalk LA, et al. 1992b. Striatal metabolic rate and clinical response to neuroleptics in schizophrenia. Arch Gen Psych 49: 966-974.
13. Burkhardt C, Kelly JP, Lim YH, Filley CM, Parker WD Jr. 1993. Neuroleptic medications inhibit complex I of the electron transport chain. Ann Neurol 33(5):512-517.
14. Caplan LR, Schmahmann JD, Kase CS, Feldmann E, Baquis G, Greenberg JP, et al. 1990. Caudate infarcts. Arch Neurol 47(2):133-43.
15. Carlsson A. 1978. Antipsychotic drugs, neurotransmitters, and schizophrenia. Am J Psychiatr 135(2):165-173.
16. Cavelier L, Jazin EE, Eriksson I, Prince J, Bave U, Oreland L, Gyllensten U. 1995. Decreased cytochrome-c oxidase activity and lack of age-related accumulation of mitochondrial DNA deletions in the brains of schizophrenics. Genomics 29(1): 217-224.
17. Chakos MH, Lieberman JA, Bilder RM, Borenstein M, Lerner G, Bogerts B, et al. 1994. Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. Am J Psychiatr 151(10):1430-1436.
18. Chang DT, Reynolds IJ. 2006. Mitochondrial trafficking and morphology in healthy and injured neurons. Prog Neurobiol 80(5):241-268.
19. De Jong LW, van der Hiele K, Veer IM, Houwing JJ, Westendorp RG, Bollen EL, et al. 2008. Strongly reduced volumes of puta-men and thalamus in Alzheimer's disease: an MRI study. Brain 131:3277-3285.
20. Deep-Soboslay A, Akil M, Martin CE, Bigelow LB, Herman MM, Hyde TM, Kleinman JE. 2005. Reliability of psychiatric diagnosis in postmortem research. Biol Psychiatry 57(1):96-101.
21. Duchen MR, Verkhratsky A, Muallem S. 2008. Mitochondria and calcium in health and disease. Cell Calcium 1:1-5.
22. Eyles DW, Pond SM, Van der Schyf CJ, Halliday GM. 2000. Mitochondrial ultrastructure and density in a primate model of persistent tardive dyskinesia. Life Sci 66(14):1345-1350.
23. Ezrin-Waters C, Seeman MV, Seeman P. 1981. Tardive dyskinesia in schizophrenic outpatients: prevalence and significant variables. J Clin Psychol 42(1):16-22.
24. Geinisman Y, Gundersen HJ, van der Zee E, West MJ. 1996. Unbiased stereological estimation of the total number of synapses in a brain region. J Neurocytol 25(12):805-819.
25. Goldman-Rakic PS. 1999. The physiological approach: functional architecture of working memory and disordered cognition in schizophrenia. Biol Psychiatr 46(5):650-661.
26. Gunter TE. 1994. Cation transport by mitochondria. J Bioenerg Biomembr 26(5):465-469.
27. Grahn JA, Parkinson JA, Owen AM. 2008. The role of the basal ganglia in learning and memory: neuropsychological studies. Prog Neurobiol 86:141-155.
28. Grahn JA, Parkinson JA, Owen AM. 2009. The cognitive functions of the caudate nucleus. Behav Brain Res 199:53-60.
29. Gur RE, Maany V, Mozley PD, Swanson C, Bilker W, Gur RC. 1998. Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia. Am J Psychiatr 155(12):1711-1717.
30. Haber SN, Fudge JL, McFarland NR. 2000. Striatonigrostriatal pathways in primates form an ascending spiral from the shell to the dorsolateral striatum. J Neurosci 15;20(6):2369-2382.
31. Harrison PJ. 1999. The neuropathological effects of antipsychotic drugs. Schizophr Res 40(2):87-99.
32. Harrison PJ, Weinberger DR. 2005. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychol 10(1):40-68.
33. Howes OD, Kapur S. 2009. The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophr Bull 35(3):549-562.
34. Karry R, Klein E, Ben Shachar D. 2004. Mitochondrial complex I subunits expression is altered in schizophrenia: a postmortem study. Biol Psychol 55(7):676-684.
35. Keedy SK, Rosen C, Khine T, Rajarethinam R, Janicak PG, Sweeney JA. 2009. An fMRI study of visual attention and sensorimotor function before and after antipsychotic treatment in first-episode schizophrenia. Psychiatry Res 172(1): 16-23.
36. Keshavan MS, Rosenberg D, Sweeney JA, Pettegrew JW. 1998. Decreased caudate volume in neuroleptic-naive psychotic patients. Am J Psychiatr 55(6):774-778.
37. Kirkpatrick B, Conley RC, Kakoyannis A, Reep RL, Roberts RC. 1999. Interstitial cells of the white matter in the inferior parietal cortex in schizophrenia: An unbiased cell-counting study. Synapse 34:95-102.
38. Kung L, Roberts RC. 1999. Mitochondrial pathology in human schizophrenic striatum: a postmortem ultrastructural study. Synapse 31(1):67-75.
39. Lewis DA, Lieberman JA. 2000. Catching up on schizophrenia: natural history and neurobiology. Neuron 28(2):325-334.
40. Li Z, Okamoto K, Hayashi Y, Sheng M. 2004. The importance of dendritic mitochondria in the morphogenesis and plasticity of spines and synapses. Cell 119(6):873-887.
41. 2 dopamine receptors. J Neurochem 44 (3): 856-861.
42. Maurer I, Zierz S, Moller H. 2001. Evidence for a mitochondrial oxidative phosphorylation defect in brains from patients with schizophrenia. Schizophr Res 48(1):125-136.
43. McFarland NR, Haber SN. 2002. Thalamic relay nuclei of the basal ganglia form both reciprocal and nonreciprocal cortical connections, linking multiple frontal cortical areas. J Neurosci 22:8117-8132.
44. Meshul CK, Janowsky A, Casey DE, Stallbaumer RK, Taylor B. 1992. Effect of haloperidol and clozapine on the density of "perforated"synapses in caudate, nucleus accumbens, and medial prefrontal cortex. Psychopharmacology (Berlin) 106(1): 45-52.
45. Miller KE, Sheetz MP. 2004. Axonal mitochondrial transport and potential are correlated. J Cell Sci 117(13):2791-2804.
46. Mitelman SA, Canfield EL, Chu KW, Brickman AM, Shihabuddin L, Hazlett EA, Buchsbaum MS. 2009. Poor outcome in chronic schizophrenia is associated with progressive loss of volume of the putamen. Schizophr Res 113:241-245.
47. Perez-Costas E, Melendez-Ferro M., Roberts RC. 2010. Basal ganglia pathology in schizophrenia: dopamine connections and anomalies. J Neurochem 113(2):287-302.
48. Pieczenik SR, Neustadt J. 2007. Mitochondrial dysfunction and molecular pathways of disease. Exp Mol Pathol 83(1): 84-92.
49. Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT, Griffin JL, et al. 2004. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychol 9(7):684-697.
50. Prince JA, Yassin MS, Oreland L. 1997. Neuroleptic-induced mitochondrial enzyme alterations in the rat brain. J Pharmacol Exp Ther 1:261-267.
51. Prince JA, Blennow K, Gottfries CG, Karlsson I, Oreland L. 1999. Mitochondrial function is differentially altered in the basal ganglia of chronic schizophrenics. Neuropsychopharmacology 21(3):372-379.
52. Prince JA, Harro J, Blennow K, Gottfries CG, Oreland L. 2000. Putamen mitochondrial energy metabolism is highly correlated to emotional and intellectual impairment in schizophrenics. Neuropsychopharmacology 22(3):284-292.
53. Rezin GT, Amboni G, Zugno AI, Quevedo J, Streck EL. 2009. Mitochondrial dysfunction and psychiatric disorders. Neurochem Res 34(6):1021-1029.
54. Roberts RC. 2001. Effect of chronic olanzapine treatment on stri-atal synaptic organization. Synapse 39:8-15.
55. Roberts RC, Gaither LA, Gao X-M, Kashyap SM, Tamminga CA. 1995. Ultrastructural correlates of haloperidol-induced oral dyskinesias in rat striatum. Synapse 20:234-243.
56. Roberts RC, Roche JK, Conley R. 2005a. Synaptic differences in the postmortem striatum of subjects with schizophrenia: a stereological ultrastructural analysis. Synapse 56:185-197.
57. Roberts RC, Roche JK, Conley RR. 2005b. Synaptic differences in the patch matrix compartments of the striatum of subjects with schizophrenia: a postmortem ultrastructural analysis. Neurobiol Dis 20:324-335.
58. Roberts RC, Roche JK, Conley RR. 2008. Differential synaptic changes in the striatum of subjects with undifferentiated versus paranoid schizophrenia. Synapse 62(8):616-627.
59. Roberts RC, Roche JK, Conley RR, Lahti AC. 2009. Dopamin-ergic synapses in the caudate of subjects with schizophrenia: relationship to treatment response. Synapse 63(6):520-530.
60. Salzman S, Endicott J, Clayton P, Winokur G. 1983. Diagnostic evaluation after death (DEAD). Rockville, MD: National Institute of Mental Health, Neuroscience Research Branch.
61. Scheepers FE, de Wied CC, Hulshoff Pol HE, van de Flier W, van der Linden JA, Kahn RS. 2001. The effect of clozapine on caudate nucleus volume in schizophrenic patients previously treated with typical antipsychotics. Neuropsychopharmacology 24(1):47-54.
62. Shihabuddin L, Buchsbaum MS, Hazlett EA, Haznedar MM, Harvey PD, Newman A, et al. 1998. Dorsal striatal size, shape, and metabolic rate in never-medicated and previously medicated schizophrenics performing a verbal learning task. Arch Gen Psychiatr 55(3):235-243.
63. Simpson EH, Kellendonk C, Kandel E. 2010. A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia. Neuron 65(5):585-596.
64. Somerville SM, Conley R, Knickman JK, Roberts RC. 2002. Electron microscopic analyses of mitochondria in postmortem striatum from patients with schizophrenia. Soc Neurosci Abstr 28:704.13.
65. Spitzer RL, Williams JB, Gibbon M, First MB. 1992. The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description. Arch Gen Psychiatr 49(8):624-629.
66. Streck EL, Rezin GT, Barbosa LM, Assis LC, Grandi E, Quevedo J. 2007. Effect of antipsychotics on succinate dehydrogenase and cytochrome oxidase activities in rat brain. Naunyn Schmiedebergs Arch Pharmacol 376(1-2):127-133.
67. Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM, et al. 1999. Molecular characterization of mitochon-drial apoptosis-inducing factor. Nature 397(6718):441-446.
68. Tarsy D, Baldessarini RH. 1977. The pathophysiological basis of tardive dyskinesia. Biol Psychiatr 12: 431-450.
69. Tsai G, Coyle JT. 2002. Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol 42:165-179.
70. Uranova NA, Orlovskaya DD, Apel K, Klintsova AJ, Haselhorst U, Schenk H. 1991. Morphometric study of synaptic patterns in the rat caudate nucleus and hippocampus under haloperidol treatment. Synapse 7(4):253-259.
71. Uranova NA, Casanova MF, DeVaughn NM, Orlovskaya DD, Denisov DV. 1996. Ultrastructural alterations of synaptic contacts and astrocytes in postmortem caudate nucleus of schizophrenic patients. Schizophr Res 22(1):81-83.
72. Uranova N, Orlovskaya D, Vikhreva O, Zimina I, Kolomeets N, Vostrikov V, Rachmanova V. 2001. Electron microscopy of oli-godendroglia in severe mental illness. Brain Res Bull 55(5): 597-610.
73. Wong-Riley MT. 1989. Cytochrome oxidase: an endogenous metabolic marker for neuronal activity. Trends Neurosci 12(3): 94-101.